Long Circulating Polymeric Nanoparticles for Gene/Drug Delivery

Hu, Jiaming; Yan, Sheng; Shi, Junfeng; Yu, Bohao; Yu, Zhiqiang; Liao, Guochao

doi:10.2174/1389200219666171207120643

Cited by 98 publications

(42 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Polymeric nanoparticles provide significant stability, high drug loading ability, controlled drug release, and excellent biocompatibility, thus was widely applied as gene and drug delivery system. [18][19][20] In our previous study, colorectal cancer was treated with 5-Fluorouracil (5-FU) and enhanced GFP (EGFP) codelivered polymeric nanoparticles and achieved effective combination results. 21 Lipid nanoparticles/liposomes are biocompatible and can be used for the specific delivery of gene/drug to tumor tissues and also render them long circulatory lifetime.…”

Section: Introductionmentioning

confidence: 99%

<p>Hyaluronic Acid Capped, Irinotecan and Gene Co-Loaded Lipid-Polymer Hybrid Nanocarrier-Based Combination Therapy Platform for Colorectal Cancer</p>

Wang¹,

Zang²,

Wei³

et al. 2020

DDDT

View full text Add to dashboard Cite

Background: The current approach for treating colorectal cancer favors the use of drug and gene combination therapy, and targeted nano-systems are gaining considerable attention for minimizing toxicity and improving the efficacy of anticancer treatment. The aim of this study was to develop ligand-modified, irinotecan and gene co-loaded lipid-polymer hybrid nanocarriers for targeted colorectal cancer combination therapy. Methods: Hyaluronic acid modified, irinotecan and gene co-loaded LPNs (HA-I/D-LPNs) were prepared using a solvent-evaporation method. Their average size, zeta potential, drug and gene loading capacity were characterized. The in vitro and in vivo gene transfection and anti-tumor ability of this nano-system were evaluated on colorectal cancer cells and mice bearing colorectal cancer model. Results: HA-I/D-LPNs had a size of 182.3 ± 5.1, over 80% drug encapsulation efficiency and over 90% of gene loading capacity. The peak plasma concentration (C max) and half-life (T 1/2) achieved from HA-I/D-LPNs were 41.31 ± 1.58 μg/mL and 12.56 ± 0.67 h. HA-I/ D-LPNs achieved the highest tumor growth inhibition efficacy and the most prominent transfection efficiency in vivo. Conclusion: HA-I/D-LPNs exhibited the most remarkable tumor inhibition efficacy and best gene transfection efficiency in the tumor, which could prove the effects of the drug and gene combination therapy.

show abstract

Section: Introductionmentioning

confidence: 99%

<p>Hyaluronic Acid Capped, Irinotecan and Gene Co-Loaded Lipid-Polymer Hybrid Nanocarrier-Based Combination Therapy Platform for Colorectal Cancer</p>

Wang¹,

Zang²,

Wei³

et al. 2020

DDDT

View full text Add to dashboard Cite

show abstract

“…After the attachment of RB and IR‐780, methoxy‐PEG acetic acid was conjugated to the nanoparticles utilizing a similar synthetic approach. PEG‐conjugated nanoparticles are known to have improved biocompatibility, with reduced immunogenicity, antigenicity and protein rejection; and longer circulation time in vivo, which increases tumor uptake of the nanoparticles . The resulting PEG‐modified nanoparticles here had slightly increased hydrodynamic diameter, as determined by DLS, indicative of multilayers of PEG on the surface (Figure ).…”

Section: Resultsmentioning

confidence: 93%

Design, synthesis and photocytotoxicity of upconversion nanoparticles: Potential applications for near‐infrared photodynamic and photothermal therapy

Honek

Wilson

et al. 2019

Journal of Biophotonics

View full text Add to dashboard Cite

Photodynamic therapy (PDT) and photothermal therapy (PTT) are emerging modalities for the treatment of tumors and nonmalignant conditions, based on the use of photosensitizers to generate singlet oxygen or heat, respectively, upon light (laser) irradiation. They have potential advantages over conventional treatments, being minimally invasive with precise spatial-temporal selectivity and reduced side effects. However, most clinically employed PDT agents are activated at visible (vis) wavelengths for which the tissue penetration and, hence, effective treatment depth are compromised. In addition, the lipophilicity of near-infrared (NIR) photothermal agents limits their use and efficiency. To achieve combined PDT/PTT effects, both excitation wavelengths need to be tuned into the NIR spectral window of biological tissues. This paper reports the synthesis of neodymium-doped upconversion nanoparticles (NaYF 4 :Yb,Er,Nd@NaYF 4 :Nd) that convert 800 nm light into vis wavelengths, which can then activate conventional photosensitizers on the nanoparticle surface for PDT. Covalently bonded IR-780 dyes can readily be activated by 800 nm laser irradiation. The PEGylated nanoplatform exhibited a narrow size distribution, good stability and efficient generation of singlet oxygen under laser irradiation. The in vitro photocytotoxicity of this engineered nanoplatform as either a PDT or PTT agent in HeLa cells is demonstrated, while fluorescence microscopy in nanoplatform-incubated cells highlights its potential for bioimaging.

show abstract

“…After subcutaneous injection small PEGylated liposomes were found in larger amount in the lymph node than after intravenous or intraperitoneal injection [ 246 ]. Concerning NC clearance from the body, NC that are smaller than 8 nm are cleared renally [ 247 ], and the extent of renal clearance was shown to correlate with the extent of negative charge [ 248 ]. Biliary clearance was observed especially for particles over 200 nm and for strongly charged particles [ 249 ].…”

Section: Route Of Vaccinationmentioning

confidence: 99%

DNA Vaccines—How Far From Clinical Use?

Hobernik

Bros

2018

IJMS

388

332

View full text Add to dashboard Cite

Two decades ago successful transfection of antigen presenting cells (APC) in vivo was demonstrated which resulted in the induction of primary adaptive immune responses. Due to the good biocompatibility of plasmid DNA, their cost-efficient production and long shelf life, many researchers aimed to develop DNA vaccine-based immunotherapeutic strategies for treatment of infections and cancer, but also autoimmune diseases and allergies. This review aims to summarize our current knowledge on the course of action of DNA vaccines, and which factors are responsible for the poor immunogenicity in human so far. Important optimization steps that improve DNA transfection efficiency comprise the introduction of DNA-complexing nano-carriers aimed to prevent extracellular DNA degradation, enabling APC targeting, and enhanced endo/lysosomal escape of DNA. Attachment of virus-derived nuclear localization sequences facilitates nuclear entry of DNA. Improvements in DNA vaccine design include the use of APC-specific promotors for transcriptional targeting, the arrangement of multiple antigen sequences, the co-delivery of molecular adjuvants to prevent tolerance induction, and strategies to circumvent potential inhibitory effects of the vector backbone. Successful clinical use of DNA vaccines may require combined employment of all of these parameters, and combination treatment with additional drugs.

show abstract

Long Circulating Polymeric Nanoparticles for Gene/Drug Delivery

Abstract: Identification of novel potential coating materials with satisfied characters is an emerging field of interest in the design of long circulating polymer-based nanoparticulate gene/drug delivery.

Cited by 98 publications

References 0 publications

<p>Hyaluronic Acid Capped, Irinotecan and Gene Co-Loaded Lipid-Polymer Hybrid Nanocarrier-Based Combination Therapy Platform for Colorectal Cancer</p>

<p>Hyaluronic Acid Capped, Irinotecan and Gene Co-Loaded Lipid-Polymer Hybrid Nanocarrier-Based Combination Therapy Platform for Colorectal Cancer</p>

Design, synthesis and photocytotoxicity of upconversion nanoparticles: Potential applications for near‐infrared photodynamic and photothermal therapy

DNA Vaccines—How Far From Clinical Use?

Contact Info

Product

Resources

About